KaloBios Completes Meeting with FDA for Benznidazole
12 déc. 2016 07h30 HE
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Highlights Priority Milestones in Letter to Stakeholders
05 déc. 2016 07h30 HE
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Dec. 05, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios to Present at JMML International Symposium
29 nov. 2016 07h30 HE
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios CEO to Present at the Priority Review Voucher Summit
31 oct. 2016 07h30 HE
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios CEO to Participate in Pharmaceutical Strategy Conference
27 sept. 2016 08h00 HE
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Sept. 27, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Now Current on SEC Periodic Filings
23 sept. 2016 16h45 HE
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Sept. 23, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Files Outstanding 10-Q and 10-K for 2015
02 sept. 2016 07h30 HE
|
KaloBios Pharmaceuticals Inc.
BRISBANE, Calif., Sept. 02, 2016 (GLOBE NEWSWIRE) -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare...
KaloBios Announces Martin Shkreli’s Sale of His Stake in the Company
29 août 2016 09h25 HE
|
KaloBios Pharmaceuticals Inc.
Another crucial milestone in the KaloBios transformationShifts all focus and resources to near-term incremental value catalysts BRISBANE, Calif., Aug. 29, 2016 (GLOBE NEWSWIRE) --...
KaloBios Announces First Patient Dosed in Phase 1 Study of Lenzilumab for the Treatment of Chronic Myelomonocytic Leukemia
25 juil. 2016 07h43 HE
|
KaloBios Pharmaceuticals Inc.
Lenzilumab offers promise for the treatment of rare leukemiaCompany turns full attention to executing its neglected and rare diseases pipeline ...
KaloBios Signs Definitive Agreement with Martin Shkreli Regarding Ownership of Shares
07 juil. 2016 07h00 HE
|
KaloBios Pharmaceuticals Inc.
Provides mechanism for reduction of Mr. Shkreli’s ownership under certain circumstancesImmediately protects company by restricting his rights, actions as shareholder BRISBANE, Calif., July 07,...